Memo - Magazine of European Medical Oncology
短名 | memo |
Journal Impact | 0.57 |
国际分区 | ONCOLOGY(Q4) |
ISSN | 1865-5041, 1865-5076 |
h-index | 21 |
MEMO 是中欧肿瘤协作组 (CECOG) 和奥地利血液与肿瘤学会 (OEGHO) 的官方期刊。期刊“欧洲医学肿瘤学杂志 – MEMO”的重点是对当前研究进行专业评论与日常实践相关的血液学和肿瘤学领域的发展。因此,备忘录包括社论和评论、同行评审的原始报告、简短的评论、病例报告和争议、解释肿瘤生物学的文章和国会报告,包括合格的评论。作为一份欧洲期刊备忘录,旨在突出各个地区的当地特色,并成为介绍正在进行的临床和基础研究的论坛。
期刊主页投稿网址涉及主题 | 医学内科学生物遗传学病理肿瘤科癌症外科免疫学化学化疗生物化学放射科癌症研究心理学 |
出版信息 | 出版商: Springer-Verlag Wien,出版周期: 4 issues per year,期刊类型: journal |
基本数据 | 创刊年份: 2008,原创研究文献占比: 39.39%,自引率:0.00%, Gold OA占比: 45.87% |
期刊引文格式
这些示例是对学术期刊文章的引用,以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章,因此这些字段是可选的。有些电子期刊不提供页面范围,而是列出文章标识符。在这种情况下,使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用,以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
Advanced stage Hodgkinʼs lymphoma 2024—Update on first line treatment
2024-9-13
Importance of genetic clarification in cytopenia syndromes (childhood myelodysplastic syndrome forms)
2024-8-29
A GLOBAL CONGRESS DIGEST ON TARGETED THERAPIES IN B-CELL MALIGNANCIES Report from the European Hematology Association (EHA) 2024 Congress (hybrid), 13th – 16th June 2024
2024-8-26
Acute lymphoblastic leukemia at the 2023 ASH meeting
2024-8-22
KRAS (Kirsten rat sarcoma) in modern oncology—The molecular pathological point of view
2024-8-21
Importance of allogeneic stem cell transplantation in myelofibrosis
2024-8-12
Trends in MDS and AML from ASH 2023
2024-7-18
Novel mutated Dubin–Johnson syndrome diagnosed during acute promyelocytic leukemia treatment
2024-7-11
Updates and changes in the treatment of cervical cancer
2024-6-20
Antibody–drug conjugates (ADCs) in lung cancer treatment
2024-6-6
GATA2 deficiency: a mystery myelodysplasia
2024-6-5
Emerging drugs in breast cancer: a focus on antibody–drug conjugates and novel treatment options in luminal disease
2024-6-4
Liquid profiling for patients with advanced cancer is ready for clinical integration
2024-5-16
Antibody–drug conjugates in the treatment of lymphoid neoplasms
2024-5-1
Rare lung cancer special: a multifaceted approach
2024-5-1
Antibody–drug conjugates (ADC special)—part 1
2024-5-1
Congress update 2023—ASCO and ESMO
2024-5-1
The molecular tumor board—a key element of precision oncology
2024-4-30
NEC versus NET G3—is there a grey zone? Case report of pancreatic NET G3 with rapid disease progression
2024-4-29
Liquid biopsy in breast cancer
2024-4-23
Alternating chemotherapy with VDC-IE as effective first-line treatment in a patient with SMARCA4-deficient undifferentiated tumor
2024-4-22
The future of clinical trials—goals, ideas, and discussion
2024-4-18
American Society of Hematology (ASH) update 2023—chronic lymphocytic leukemia
2024-4-18
15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives
2024-3-26
Treatment-changing news in urogenital cancer—a brief unstructured narrative review based on findings presented at the ESMO 2023 conference
2024-3-18
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology
2024-3-13
Prediction of epidermal growth factor receptor mutation status by textural features in stage IV lung adenocarcinoma
2024-2-28
Seminal vesicle metastasis from transverse colon adenocarcinoma: a unique case report
2024-2-23
β-adrenergic modulation of IL-6/gp130 and SOCS-1 in multiple myeloma: therapeutic strategy for stress induced-inflammatory response
2024-2-9
Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations
2024-2-8
OeGHO annual meeting 2023—best of oncology
2024-2-1
Prostate cancer special—part 2
2024-2-1
“Navigating the evolving landscape of cancer treatment: a triad of progress”
2024-2-1
Innovative therapeutic concepts for biliary tumors
2024-1-29
Can artificial intelligence provide accurate and reliable answers to cancer patients’ questions about cancer pain? Comparison of chatbots based on ESMO cancer pain guideline
2024-1-26
Antibody–drug conjugates in ovarian cancer
2024-1-25
Acute myeloid leukemia patient with active disseminated tuberculosis bridged to transplant with reduced 14-day venetoclax and azacitidine schedule
2024-1-23
(Neo)adjuvant approaches in lung cancer—paving the road to a cure
2024-1-19
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
2024-1-16
Pulmonary puzzles: salivary gland-type tumors of the lung and their metastatic equivalents
2024-1-11
Transformation of epidermal growth factor receptor-mutated non-small cell lung cancer into small cell lung cancer—case report
2024-1-8
Molecular typing—new targets and therapy options for upper GI carcinomas with a focus on adenocarcinomas of the esophagus, gastroesophageal junction, and stomach
2024-1-5
Metastasis-directed therapy: new standard or too early to change paradigm?
2023-12-29
Upper-GI highlights from ASCO and ASCO-GI 2023 meetings: changing paradigm in treatment sequence
2023-12-29
Total neoadjuvant therapy for each local advanced rectal cancer?
2023-12-28
(Neo)adjuvant approaches: pavement on the road to cure—breast cancer
2023-12-19
Diagnosis and management of mediastinal extragonadal germ cell tumors
2023-12-18
Management of oligometastatic prostate cancer
2023-12-18
ASCO 2023: highlights in breast cancer
2023-12-5
Cancer of unknown primary—state of the art
2023-12-5
帮你贴心管理全部的文献
研飞ivySCI,高效的论文管理
投稿经验分享
分享我的经验,帮你走得更远